Trial: 202008066

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors

Phase

I

Principal Investigator

Johanns, Tanner

Disease Site

Colon; Melanoma, Skin; Metastatic Disease; Rectum

Learn more about this study at: clinicaltrials.gov